BioLargo Price To Earning vs. Price To Book

BLGO Stock  USD 0.20  0.01  5.26%   
Considering BioLargo's profitability and operating efficiency indicators, BioLargo may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess BioLargo's ability to earn profits and add value for shareholders.
For BioLargo profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLargo to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLargo utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLargo's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLargo over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between BioLargo's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLargo is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLargo's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

BioLargo Price To Book vs. Price To Earning Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining BioLargo's current stock value. Our valuation model uses many indicators to compare BioLargo value to that of its competitors to determine the firm's financial worth.
BioLargo is rated below average in price to earning category among its peers. It is rated third in price to book category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLargo by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLargo's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

BioLargo Price To Book vs. Price To Earning

Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

BioLargo

P/E

 = 

Market Value Per Share

Earnings Per Share

 = 
(4.54) X
Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

BioLargo

P/B

 = 

MV Per Share

BV Per Share

 = 
10.61 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

BioLargo Price To Book Comparison

BioLargo is currently under evaluation in price to book category among its peers.

BioLargo Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in BioLargo, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLargo will eventually generate negative long term returns. The profitability progress is the general direction of BioLargo's change in net profit over the period of time. It can combine multiple indicators of BioLargo, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.

BioLargo Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on BioLargo. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLargo position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLargo's important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in BioLargo without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Suggestion Now

   

Portfolio Suggestion

Get suggestions outside of your existing asset allocation including your own model portfolios
All  Next Launch Module

Use Investing Themes to Complement your BioLargo position

In addition to having BioLargo in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Baby Boomer Prospects Thematic Idea Now

Baby Boomer Prospects
Baby Boomer Prospects Theme
Equities with large market capitalization that account for significant contribution to overall economic growth especially within dividend-paying instruments and stocks from healthcare and financial sectors. The Baby Boomer Prospects theme has 99 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Baby Boomer Prospects Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in BioLargo OTC Stock

To fully project BioLargo's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioLargo at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioLargo's income statement, its balance sheet, and the statement of cash flows.
Potential BioLargo investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although BioLargo investors may work on each financial statement separately, they are all related. The changes in BioLargo's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioLargo's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.